CN115137751B - 一种富血小板血浆的处理方法及其在抑制妊娠纹中的应用 - Google Patents
一种富血小板血浆的处理方法及其在抑制妊娠纹中的应用 Download PDFInfo
- Publication number
- CN115137751B CN115137751B CN202210840424.3A CN202210840424A CN115137751B CN 115137751 B CN115137751 B CN 115137751B CN 202210840424 A CN202210840424 A CN 202210840424A CN 115137751 B CN115137751 B CN 115137751B
- Authority
- CN
- China
- Prior art keywords
- platelet
- rich plasma
- prp
- striae gravidarum
- activator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004623 platelet-rich plasma Anatomy 0.000 title claims abstract description 71
- 206010040925 Skin striae Diseases 0.000 title claims abstract description 38
- 238000011282 treatment Methods 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims abstract description 16
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 6
- 239000012190 activator Substances 0.000 claims abstract description 15
- OXHYRVSBKWIFES-WWSDOYNLSA-N trap-14 peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=CC=C1 OXHYRVSBKWIFES-WWSDOYNLSA-N 0.000 claims abstract description 9
- 210000005259 peripheral blood Anatomy 0.000 claims abstract description 5
- 239000011886 peripheral blood Substances 0.000 claims abstract description 5
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 10
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 10
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 10
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 10
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 5
- 231100000241 scar Toxicity 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 208000032544 Cicatrix Diseases 0.000 claims description 2
- 230000037387 scars Effects 0.000 claims description 2
- 230000008901 benefit Effects 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 10
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 9
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 9
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 230000037394 skin elasticity Effects 0.000 description 8
- 210000001015 abdomen Anatomy 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 208000031439 Striae Distensae Diseases 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
- 102000013275 Somatomedins Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000010836 blood and blood product Substances 0.000 description 3
- 229940125691 blood product Drugs 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000013532 laser treatment Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 238000010146 3D printing Methods 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003721 gunpowder Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003634 thrombocyte concentrate Substances 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/19—Platelets; Megacaryocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0644—Platelets; Megakaryocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种富血小板血浆的处理方法及其在抑制妊娠纹中的应用,其特征在于将外周血采用离心机进行分离得到富血小板血浆,所得到富血小板血浆经过激活剂激活,所述激活剂中含有CaCl2和凝血酶受体激动剂肽6。本发明将富血小板血浆应用于治疗妊娠纹具有很高的成功率;不仅能够帮助大量女性减轻妊娠纹方面的苦恼,还能够获得经济效益。
Description
技术领域
本发明属于医药生物技术领域,具体涉及一种富血小板血浆的处理方法及其在抑制妊娠纹中的应用。
背景技术
妊娠纹(Striaegravidarum,SG)是女性孕期增大的子宫及激素变化导致局部皮肤弹性纤维蛋白分解、断裂而出现的红色、紫色或白色条纹样病损。初产妇妊娠纹患病率高达50%以上,且一旦形成将终生不退,严重破坏腹部美观。妊娠纹早期治疗以外用药物为主,近年来出现了一些先进治疗模式,如二氧化碳剥脱性点阵激光治疗、射频技术和微针治疗等,但相关报道较少,效果也各不相同,缺乏系统性研究成果,因此目前尚不存在可有效治疗妊娠纹且副作用小的共识模式,也尚无临床治疗指南供参考。由此可见,系统评价妊娠纹治疗方案的临床疗效,并进一步研究治疗方案的作用机制,对于指导妊娠纹治疗意义重大。
治疗妊娠纹的核心目标是促进皮肤组织生长、恢复皮肤弹性、避免感染和消除疤痕,这些过程与伤口愈合十分相似,而富血小板血浆(platelet-richplasma,PRP)则是非常匹配的治疗方法。PRP是一种自体全血经离心后得到的血小板浓缩物,主要包含高浓度血小板、白细胞和纤维蛋白,其中血小板被激活后,能够释放多种生长因子如血小板源性生长因子(PDGF)、转化生长因子(TGF-β)、胰岛素样生长因子(IGF)、表皮生长因子(EGF)和血管内皮细胞生长因子(VEGF)以及一些促凝因子等,这些因子能够加速损伤组织的修复过程,因此被广泛应用于骨科、心脏外科、妇科、整形外科等很多不同医学领域。在皮肤科领域,PRP已被发现具有促进组织再生,伤口愈合,疤痕修复,皮肤更新等功能,并且由于PRP具有自源性,能够避免外源性生长因子引起的免疫排斥反应或疾病传染风险,因此越来越受到关注。
PRP的功能与治疗妊娠纹的核心目标很一致。在促进皮肤组织生长方面,PRP中TGF-β可提高皮肤角化细胞的增殖能力和迁移速度,EGF能够促进表皮细胞和成纤维细胞的分裂增殖作用,IGF、PDGF和VEGF可促进内皮细胞增殖和向创伤部位迁移,并诱导新生血管形成,从而为其他细胞生长和毛细血管网的建立提供营养;在恢复皮肤弹性方面,PRP中TGF-β、EGF、VEGF等因子均可促进Ⅰ、Ⅲ型胶原蛋白和透明质酸的合成,TGF-β还可抑制细胞外基质降解,激活纤维蛋白构成皮肤支架,由此提高皮肤弹性,缓解皮肤失水和松弛;在避免感染方面,PRP中含有大量的白细胞和单核细胞,可清除局部病原体和局部坏死组织,能够显著增强局部抗感染能力;以上作用均可推动疤痕消除。由此可见,PRP非常适合治疗妊娠纹,很可能具有显著疗效,但目前将PRP应用于妊娠纹临床治疗的报道极少,因此需要开展更加系统和深入的研究。
在中国专利申请CN109069360A,其公开了一种用于透皮施用血液产品的组分的皮肤护理制剂,所述制剂包含血液产品、透皮载体;和脂质体基质,其中所述血液产品和透皮载体的至少一部分包含在所述脂质体基质的脂质体内。其虽然泛泛提及了富血小板血浆的透皮施用有可能能够改善妊娠纹,但其并未提供任何实验数据证明这一点,特别是其并未针对妊娠纹对富血小板血浆的提取方法进行研究。
针对PRP的外用制剂,中国专利申请CN112915264A公开了用于明胶-海藻酸钠-PRP复合材料的制作方法,在10%明胶、4%海藻酸钠的混合预凝胶中,其他条件、交联剂、打印工艺不变,在交联前混入不同浓度(初步预实验发现5%浓度效果最佳)的富血小板血浆,混合均匀,该混合体系作为皮肤替代物3D打印的墨水材料。从而对原有的墨水做了改性,提高了材料的细胞相容性、组织修复能力,更有利于临床转化应用。
PRP中的血小板浓度和血小板激活后释放的活性物质是其发挥功效的首要影响因素,特殊人群和服用药物等情况会影响血小板功能,其浓缩后的生物学效用差别极大,这可能导致PRP的治疗效果不明显。因此为了更稳定地应用PRP治疗妊娠纹,PRP中关键药效成分的含量与治疗效果的关系需要受到关注。
发明内容
基于上述原因,本发明提出一种富血小板血浆的处理方法及其在抑制妊娠纹中的应用。具体而言,为了实现本发明的目的,本发明拟采用如下的技术方案:
本发明一方面涉及一种富血小板血浆的处理方法,其特征在于将外周血采用离心机进行分离得到富血小板血浆,所得到富血小板血浆经过激活剂激活,所述激活剂中含有CaCl2和凝血酶受体激动剂肽6。
在本发明的一个优选实施方式中,所述激活剂中CaCl2的浓度为4~12wt%;优选为4~6wt%。
在本发明的一个优选实施方式中,所述激活剂中凝血酶受体激动剂肽6的浓度0.5~1.5wt%;优选为0.8~1.2wt%。
在本发明的一个优选实施方式中,所述激活剂和富血小板血浆的体积比为8~10:1。
在本发明的一个优选实施方式中,所述富血小板血浆的血小板浓度为1.1~1.5×1012/L。
在本发明的一个优选实施方式中,所述激活包括如下步骤:将激活剂与富血小板血浆混合,室温静止8-12min,离心,提取萃取液。
在本发明的一个优选实施方式中,所述萃取液中PDGF、TGF-β、VEGF的浓度分别为370-400ng/ml、1800-1950ng/ml、1120-1200pg/ml。
本发明另一方面涉及上述处理方法所获得的经激活的富血小板血浆。
本发明还涉及上述经激活的富血小板血浆在抑制皮肤瘢痕中的应用,优选的,所述皮肤瘢痕是指妊娠纹。
在本发明的一个优选实施方式中,所述经激活的富血小板血浆是自源性的。
有益效果
本发明将PRP应用于治疗妊娠纹可有效利用PRP的核心优势,如:①PRP具有自源性,可避免外源性生长因子进入人体后引起的免疫排斥反应或疾病传染风险;②PRP制备简单、快捷、方法成熟,易于操作和推广;③PRP中含多种高浓度生长因子协同作用,可弥补单一因子的不足;④PRP的制备只需采集患者的外周血,对患者损伤小;⑤PRP具有激活免疫反应、促进血管生成、推动组织再生等多种与治疗妊娠纹非常匹配的功能,因此既具有创新性,又具有很高的成功率;不仅能够帮助大量女性减轻妊娠纹方面的苦恼,还能够获得经济效益。
具体实施方式
为了进一步理解本发明,下面将结合本发明实施例,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
如无特殊说明,本发明实施例中所涉及的试剂均为市售产品,均可以通过商业渠道购买获得。
实施例1:
收集30名妊娠纹患者的外周血,采用离心机进行离心,第1次离心1600r/min,10min;第2次离心5000r/min,5min。离心后提取PRP,第1次离心后收集全部血浆层、白膜层及2~3mm范围的红细胞层移至另一采血管;第2次离心后抽取3/4血浆层,即贫血小板血浆(platelet-poolplasma,PPP),余下的1/4即PRP。离心获得的PRP经检验血小板浓度为1.2×1012/L,符合实验要求。提取PRP后,将PRP分为4组:第1组未激活PRP;第2组只加10%CaC1激活;第3组加5wt%CaCl2和1wt%凝血酶受体激动剂肽6激活;第4组加10wt%CaCl2和1wt%凝血酶受体激动剂肽6激活。3种激活剂均按9:1(v/v)与PRP混合,室温静止10min,离心12000r/min,5min,提取萃取液。ELISA方法比较不同激活方法获得的PRP的PDGF、TGF-β、VEGF的浓度差异。其中,均采用ELISA方法进行检测,检测重复3次,检测结果如表1所示。
表1:PRP激活后PDGF、TGF-β、TGF-β的浓度
实验结果表明,激活组相比于未激活组,PRP的PDGF、TGF-β、VEGF的浓度都有所提高,特别是5wt%CaCl2+凝血酶受体激动剂肽6相比于其它组,PRP的PDGF、TGF-β、VEGF的浓度提高更为明显,相比于其它组具有显著性差异(P<0.05)。
实验例2:药效学实验
(1)入组标准
2021年10月1日至2022年1月31日在东莞市妇幼保健院皮肤科就诊的妊娠纹患者40例;
①18-50岁的女性妊娠纹受试者;
②腹部有妊娠纹(红纹或白纹均可)。
(2)剔除标准
①凝血功能障碍;
②具有瘢痕体质患者;
③半年内曾对治疗部位有治疗者;
④2个月内曾使用过维A酸类药物及其衍生物;
⑤孕妇、哺乳期妇女;
⑥对治疗期望值过高者;
⑦对局部涂抹麻药过敏者;
⑧有严重肝、肾功能损害等系统疾病的患者。
(3)PRP治疗
就医者取仰卧位,注射区域外涂复方利多卡因乳膏8~10g,用塑料保鲜膜封包1h进行表面麻醉后,采用套装中配套的注射器配27G针头抽取PRP(5wt%CaCl2+凝血酶受体激动剂肽6激活),进行腹部皮下注射,每点注射量0.1mL,每点针距约1cm,与皱纹平行刺入真皮浅层,边退针边注射,使PRP尽量填充皮肤凹陷处,注射过程中按压止血。嘱患者注射后当日腹部避免沾水及按摩揉捏,1周内禁饮酒及禁食辛辣刺激食物,避免蒸桑拿等可能诱发腹部毛细血管扩张的行为。每个月一次,共三次。
(4)CO2剥脱性点阵激光治疗
治疗前患者清洁腹部,外用复方利多卡因乳膏涂抹治疗区,封包40~60min,治疗前清洗局麻乳膏。治疗时光斑不重叠,治疗结束后立即用冰袋冷敷10~15min,采用10600nmCO2点阵激光治疗。治疗频率:每次治疗间隔2个月,共治疗3次,末次治疗结束后随访3个月。
(5)临床评价
①总有效率评价:由2名医师和患者共同评价妊娠纹的外观表现和数码照片,分为显效(妊娠纹明显改善,患者满意)、有效(妊娠纹改善,患者较满意)和无效3类(妊娠纹无明显变化,患者不满意)。总有效率=(显效+有效)例数/总例数×100%。
②皮肤弹性评价:采用皮肤弹性测量仪测量患者腹部妊娠纹区域皮肤总弹性指数,指数越接近1,表示皮肤弹性越好。
临床评价结果如表2所示。
实验结果表明,相比于激光治疗组,PRP治疗组的总有效率更高,对于皮肤弹性指数的改善也更明显,两组间具有显著性差异(P<0.05)。
以上描述了本发明优选实施方式,然其并非用以限定本发明。本领域技术人员对在此公开的实施方案可进行并不偏离本发明范畴和精神的改进和变化。
Claims (3)
1.一种富血小板血浆的处理方法,其特征在于将外周血采用离心机进行分离得到富血小板血浆,所得到富血小板血浆经过激活剂激活,所述激活剂中含有CaCl2和凝血酶受体激动剂肽6,将激活剂与富血小板血浆混合,室温静止8-12min,离心,提取萃取液,所述萃取液中PDGF、TGF-β、VEGF的浓度分别为370-400ng/ml、1800-1950ng/ml、1120-1200pg/ml;所述激活剂中CaCl2的浓度为4~6wt%;所述激活剂中凝血酶受体激动剂肽6的浓度为1wt%,所述激活剂和富血小板血浆的体积比为8~10:1,所述富血小板血浆的血小板浓度为(1.1~1.5)×1012/L。
2.权利要求1所述处理方法所获得的经激活的富血小板血浆在制备抑制皮肤瘢痕的药物中的应用,所述皮肤瘢痕是指妊娠纹。
3.根据权利要求2所述的应用,所述经激活的富血小板血浆是自源性的。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210840424.3A CN115137751B (zh) | 2022-07-18 | 2022-07-18 | 一种富血小板血浆的处理方法及其在抑制妊娠纹中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210840424.3A CN115137751B (zh) | 2022-07-18 | 2022-07-18 | 一种富血小板血浆的处理方法及其在抑制妊娠纹中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115137751A CN115137751A (zh) | 2022-10-04 |
CN115137751B true CN115137751B (zh) | 2024-05-28 |
Family
ID=83412168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210840424.3A Active CN115137751B (zh) | 2022-07-18 | 2022-07-18 | 一种富血小板血浆的处理方法及其在抑制妊娠纹中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115137751B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101134011A (zh) * | 2007-08-13 | 2008-03-05 | 北京赛尔泰和生物医药科技有限公司 | 一种注射用人体皮肤损伤修复注射剂 |
CN110585240A (zh) * | 2019-10-10 | 2019-12-20 | 广州医科大学附属第三医院(广州重症孕产妇救治中心、广州柔济医院) | 一种含再生因子的冻干制剂及其制备方法和应用 |
CN113244458A (zh) * | 2021-05-08 | 2021-08-13 | 康膝生物医疗(深圳)有限公司 | 一种用于修复关节软骨损伤的复合材料及其制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030198687A1 (en) * | 2002-04-18 | 2003-10-23 | Keith Bennett, M.D. | Wound care composition |
US20060293231A1 (en) * | 2004-07-30 | 2006-12-28 | Regina Landesberg | Method for enhancing bone formation |
ITRM20040638A1 (it) * | 2004-12-24 | 2005-03-24 | Advance Holdings Ltd | Gel piastrinico semisintetico e metodo per la sua preparazione. |
-
2022
- 2022-07-18 CN CN202210840424.3A patent/CN115137751B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101134011A (zh) * | 2007-08-13 | 2008-03-05 | 北京赛尔泰和生物医药科技有限公司 | 一种注射用人体皮肤损伤修复注射剂 |
CN110585240A (zh) * | 2019-10-10 | 2019-12-20 | 广州医科大学附属第三医院(广州重症孕产妇救治中心、广州柔济医院) | 一种含再生因子的冻干制剂及其制备方法和应用 |
CN113244458A (zh) * | 2021-05-08 | 2021-08-13 | 康膝生物医疗(深圳)有限公司 | 一种用于修复关节软骨损伤的复合材料及其制备方法 |
Non-Patent Citations (11)
Title |
---|
Efficacy of ablative fractional carbon dioxide laser combined with autologous platelet-rich plasma versus ablative fractional carbon dioxide laser and placebo in the treatment of striae gravidarum: A randomized clinical trial;Ivan Arni C Preclaro et al;J Cosmet Dermatol.;第21卷(第10期);全文 * |
Hend D Gamil et al.Platelet-Rich Plasma Versus Tretinoin in Treatment of Striae Distensae: A Comparative Study.Dermatologic Surgery.2018,第44卷(第5期),打印文档第1页摘要,第2页右栏倒数第1段-第3页左栏第1段、图1. * |
PGFs及其制备方法的研究进展;于晶晶等;中国输血杂志;20110925;24(9);第817-821页 * |
Platelet-Rich Plasma Versus Tretinoin in Treatment of Striae Distensae: A Comparative Study;Hend D Gamil et al;Dermatologic Surgery;第44卷(第5期);打印文档第1页摘要,第2页右栏倒数第1段-第3页左栏第1段、图1 * |
PRP在瘢痕防治中的作用机制研究进展;胡再昌等;中国美容医学;第28卷(第12期);第174页左栏第3段 * |
侯晓媛等.富血小板血浆在皮肤科中的应用进展.中华皮肤科杂志.2019,52(004),全文. * |
富血小板血浆促进骨再生与修复的影响因素研究进展;赵耀等;富血小板血浆促进骨再生与修复的影响因素研究进展;第24卷(第8期);第1005页右栏第1段,左栏倒数第1段 * |
富血小板血浆在皮肤科中的应用进展;侯晓媛等;中华皮肤科杂志;52(004);全文 * |
富血小板血浆提取方法的探讨;王悦等;实用口腔医学杂志;第27卷(第5期);第644页左栏倒数第1段-右栏第1段 * |
王悦等.富血小板血浆提取方法的探讨.实用口腔医学杂志.2011,第27卷(第5期),第644页左栏倒数第1段-右栏第1段. * |
胡再昌等.PRP在瘢痕防治中的作用机制研究进展.中国美容医学.2019,第28卷(第12期),第174页左栏第3段. * |
Also Published As
Publication number | Publication date |
---|---|
CN115137751A (zh) | 2022-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210346587A1 (en) | New standardizations & medical devices for the preparation of platelet rich plasma (prp) or bone marrow concentrate (bmc) alone or in combination with hyaluronic acid | |
KR20080100425A (ko) | 조절된 혈액 조성물 및 이의 생산 방법 | |
JP2019513136A (ja) | 羊水による治療の組成物及び方法 | |
CN106110389A (zh) | 一种皮肤创面用的湿性敷料及其制备方法和应用 | |
Dini et al. | Eyebrow regrowth in patient with atrophic scarring alopecia treated with an autologous fat graft | |
JP2009235004A (ja) | 細胞組織増加促進方法及び肌問題改善方法並びにこれらに用いるキット | |
CN102274493B (zh) | 一种可用于微创美容疗法的止血消炎镇痛复合功效纳米乳及其制备方法 | |
CN110721343A (zh) | 一种能修复凹陷性或萎缩性瘢痕的gfg凝胶及制备方法及应用 | |
CN115137751B (zh) | 一种富血小板血浆的处理方法及其在抑制妊娠纹中的应用 | |
CN114306287A (zh) | 一种用于难愈合创伤治疗的生物膜的制备方法 | |
CN109010906B (zh) | 一种促进术后伤口局部止血及促进术后创面上皮化的生物胶水及其工作方法 | |
CN113521523A (zh) | 一种用于治疗创面的微针给药系统及其应用 | |
WO2018034595A1 (ru) | Способ лечения атрофических рубцов кожи | |
RU2629527C1 (ru) | Способ коррекции возрастных изменений мягких тканей лица и/или тела | |
Qari et al. | Combined Synergetic Effect of Lipoconcentrate Fat Grafting, Nanofat Transfer, Platelet-Rich Plasma, Microneedling, and CO2 Fractional Laser for Plastic Regenerative and Esthetic Surgery and Cosmetic Care | |
CN116370690B (zh) | 胎盘底蜕膜复合制剂、其制法,含有其的医用敷料及应用 | |
RU2753136C1 (ru) | Способ аутодермопластики расщепленным кожным лоскутом для восстановления кожного покрова при ожогах | |
CN111346230B (zh) | 一种用于术后快速镇痛消肿的医药组合物及其配置方法 | |
Patil et al. | Utility of Platelet rich plasma in medicine-A Review | |
RU2817948C2 (ru) | Способ лечения фиброза кожи | |
CN115400148A (zh) | 一种骨髓源性富血小板血浆及其制备方法和应用 | |
RU2679449C1 (ru) | Способ лечения дефектов кожи и мягких тканей у больных сахарным диабетом и способ введения препарата для него | |
Chaudhari et al. | Management of non-healing ulcers by autologous platelet rich fibrin (PRF) | |
Alnemr et al. | Evaluating the Efficacy of Facial Scar Treatment Techniques Using Nanofat Grafting: A Case Series | |
WO2015183125A1 (ru) | Способ местного лечения язвенных дефектов при синдроме диабетической стопы |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |